Related coverage linked through entity extraction aliases.
Mar 06, 2026
AbbVie is testing venetoclax in a Phase 2 study for adults with relapsed or refractory Waldenström macroglobulinemia or lymphoplasmacytic lymphoma in Japan, aiming to expand the drug into rare blood cancers.
Mar 05, 2026
The global biosimilar market is experiencing robust growth, valued at USD 36.79 billion in 2024 and projected to reach USD 282.3 billion by 2035 at a CAGR of 20.35%, driven by patent expirations, cost pressures, and expanding access to biologic therapies.
Mar 05, 2026
A nationwide survey reveals 50% of Americans don't know colorectal cancer can be screened at home, as the disease becomes the leading cause of cancer death in adults under 50. Current guidelines recommend screening begin at age 45.
Mar 05, 2026
The large molecule drug substance CDMO market is expected to grow at approximately 9% CAGR through 2031, driven by rising demand for biologics and biosimilars, streamlined regulatory approval pathways, and increasing FDA and EMA approvals for biologic therapies.
Mar 05, 2026
New research reveals that different KRAS mutation types create distinct tumor ecosystems with varying immune responses, potentially enabling personalized treatment strategies combining mutation-specific inhibitors with immunotherapy.
Mar 04, 2026
Researchers at the University of Bath have developed a bacterial system that produces, chemically stabilizes, and tests millions of peptide drug candidates inside living cells, identifying inhibitors of transcription factor CREB1 overactive in multiple cancers.
Mar 04, 2026
The global mRNA and next-generation vaccine platforms market is expected to grow from $39.69 billion in 2025 to $82.61 billion by 2030 at a 15.8% CAGR, driven by personalized medicine demand and infectious disease applications, while safety concerns and regulatory scrutiny continue.
Mar 04, 2026
Insilico Medicine has formed a strategic partnership with Liquid AI to develop lightweight scientific foundation models for drug discovery and entered a drug development collaboration with China Medical System Holdings targeting CNS and autoimmune diseases.
Mar 04, 2026
At least 111 substances of unknown safety have been added to U.S. foods, drinks and supplements without alerting the FDA, exploiting a legal loophole in the "generally recognized as safe" standard, according to a new investigation.
Mar 04, 2026
Oncology specialists are warning cancer patients against biotin supplementation, citing its capacity to distort critical laboratory test results including hormone panels used to monitor treatment and detect recurrence.
Mar 04, 2026
ImmunityBio establishes wholly owned subsidiary in Saudi Arabia to distribute Anktiva for bladder and lung cancer across MENA region, following world's first lung cancer approval in the Kingdom less than a year after May 2025 meeting.
Mar 03, 2026
University of Melbourne receives $2.1 million for quantum-enabled brain-on-chip platform for neurological diseases, while Evogene partners with Queensland University of Technology on AI-driven cancer therapeutics targeting chemotherapy resistance.
Mar 03, 2026
The global cancer gene therapy market is projected to grow from $3.6 billion in 2023 to $16 billion by 2033 at a 16.1% CAGR, while the broader oncology market eyes $748 billion by 2035, driven by immunotherapy advances and targeted treatments.
Mar 03, 2026
New initiatives aim to address social determinants of health in oncology, while research reveals persistent disparities in treatment access and clinical trial participation for Black and minority cancer patients.
Mar 03, 2026
Johnson & Johnson announced a $1 billion cell therapy manufacturing facility in Pennsylvania while reportedly exploring a sale of its DePuy Synthes orthopedics business for over $20 billion.
Mar 03, 2026
Relay Therapeutics reported full-year 2025 revenue of $15.36 million and a narrowed net loss of $276.48 million, while securing FDA Breakthrough Therapy designation for lead asset zovegalisib. The company filed a $96.18 million shelf registration.
Mar 02, 2026
Two major partnerships in India's diagnostics sector aim to strengthen precision medicine capabilities. MedGenome acquires majority stake in Medcare Management Services, while SRMIST partners with CORE Diagnostics to train future oncology professionals.
Mar 02, 2026
A CNIC study demonstrates that remote ischemic conditioning can protect the heart during anthracycline chemotherapy without compromising antitumor efficacy, while researchers explore additional methods to manage chemotherapy side effects.
Mar 02, 2026
New research demonstrates that physical activity after cancer diagnosis reduces mortality risk in less common cancers and enhances circadian clock function in tumor tissue, supporting exercise as a therapeutic intervention.
Mar 01, 2026
Anbio Biotechnology shares gained following an upgrade from a sell rating to hold. The company reported $0.04 earnings per share and $2.29 million in quarterly revenue.
